{
  "schema_version": "1.3.1",
  "doc": {
    "doc_id": "1dadca396bee768aa9610a7c3a43caef",
    "title": "BioArctic (BIOAb.ST)",
    "source_uri": "2025-09-02/BioArctic_2025-09-02",
    "language": "en",
    "timestamps": {
      "ingested_at": "2025-10-27T00:18:47.390844",
      "extracted_at": "2025-10-27T00:18:47.390853"
    },
    "extraction_run": {
      "vision_model": "deepseek-ai/DeepSeek-OCR",
      "synthesis_model": "rule-based-engine",
      "pipeline_steps": [
        "ocr",
        "rule_extraction",
        "figure_vision"
      ],
      "processing_metadata": {
        "pages_processed": 11,
        "successful_pages": 11,
        "date": "2025-09-02",
        "publication": "2025-09-02",
        "authors": [],
        "markdown_cleaning": {
          "removed_sections": 2,
          "removed_paragraphs": 4,
          "reduction_ratio": 0.04909679039333559
        },
        "input_relative_path": "2025-09-02"
      }
    }
  },
  "passages": [
    {
      "passage_id": "e816297a54cffd1c",
      "text": "BIOAb.ST 12m Price Target: Skr353.00 Price: Skr309.00 Upside: 14.2%",
      "page": 0,
      "section": null
    },
    {
      "passage_id": "ce7328427ec51423",
      "text": "BioArctic reported 2Q25 earnings which were largely in- line with expectations given the key metric of Leqembi sales had previously been reported by partners BIIB and Eisai and came in ahead of pre- results expectations aided by a one- time stocking effect in China. Management guidance for operating expenses in FY25 was lowered with the company now expecting \\(50 - 70\\%\\) growth compared to \\(60 - 80\\%\\) growth guided to at 1Q25. With financials beyond Leqembi of limited importance and key pipeline timelines on track, focus was on the company's BrainTransporter platform following announcement of a collaboration agreement with Novartis announced on 26th August. The platform is an area of increasing investor focus given that Novartis is the third large cap pharma company to collaborate with BioArctic which we believe supports initial steps to early validation of the platform supported by clinical data from competitor Roche which uses a similar transferrin approach. We see the Novartis collaboration as a key positive development for BioArctic bringing meaningful upfront cash (\\$30mn) and adding to collaborations with BMS and Eisai (Exhibit 1). Whilst we await clinical data to attribute explicit value of the collaborations in our model with the BMS partnered asset potentially entering clinical trials in 2026, we believe the three collaborations add credibility to BioArctic's technology capabilities and thus increase our terminal growth assumption and lower our WACC to reflect the potential future value given the company expects to continue to enter into collaboration agreements for the platform in neuroscience and beyond. Furthermore, we expect the additional collaboration to aid in building investor awareness of the company. Additionally, FDA approval of the Leqembi autoinjector in the maintenance setting represents another positive catalyst, in our view, which we believe should provide the market with incremental reassurance on long- term revenue expectations. We also raise our",
      "page": 0,
      "section": null
    },
    {
      "passage_id": "9eeb4947381b5cd0",
      "text": "Market cap: Skr27.3bn / \\$2.9bn Enterprise value: Skr26.3bn / \\$2.8bn 3m ADTV: Skr52.0mn / \\$5.4mn Sweden Europe Biotech M&A Rank: 3 Leases incl. in net debt & EV?: Yes",
      "page": 0,
      "section": null
    },
    {
      "passage_id": "616237ffcbff528f",
      "text": "12/2412/25E12/26E12/27ERevenue (Skr mn) New257.42,013.41,286.11,615.5Revenue (Skr mn) Old257.41,962.11,253.51,617.6EBIT (Skr mn)(228.5)1,224.5442.4639.8EPS (Skr) New(2.00)11.324.325.70EPS (Skr) Old(2.00)10.393.335.65P/E (X)NM27.371.554.2Dividend yield (%)NMNMNMNMCROCI (%)(53.3)163.821.235.1N debt/EBITDA (ex lease,X)-(0.8)(3.0)(2.7)",
      "page": 0,
      "section": null
    },
    {
      "passage_id": "940a9b19a25cc177",
      "text": "EPS (Skr)3/256/259/25E12/25EEPS (Skr)11.551.09(1.00)(0.33)",
      "page": 0,
      "section": null
    },
    {
      "passage_id": "6da0062a00531bf9",
      "text": "Source: Company data, Goldman Sachs Research estimates. See disclosures for details.",
      "page": 0,
      "section": null
    },
    {
      "passage_id": "7d76ee80ccbb05c7",
      "text": "Goldman Sachs does and seeks to do business with companies covered in its research reports. As a result, investors should be aware that the firm may have a conflict of interest that could affect the objectivity of this report. Investors should consider this report as only a single factor in making their investment decision. For Reg AC certification and other important disclosures, see the Disclosure Appendix, or go to www.gs.com/research/hedge.html. Analysts employed by non- US affiliates are not registered/qualified as research analysts with FINRA in the U.S.",
      "page": 0,
      "section": null
    },
    {
      "passage_id": "9e1b34dc6b0e0d81",
      "text": "BuyBioArctic (BIOAb.ST) Rating since Dec 11, 2023",
      "page": 1,
      "section": null
    },
    {
      "passage_id": "fc24a72b763bd1ea",
      "text": "Ratios & Valuation12/2412/25E12/26E12/27EEV/sales (X)66.413.120.315.9Net PFEEV/EBITDAR (X)NM21.559.040.1Net intangiblesEV/EBITDA (excl. leases) (X)NM21.760.941.2Total investmentsEV/EBIT (X)NM21.559.040.1Other long-term assetsP/E (X)NM27.371.554.2Total assetsDividend yield (%)0.00.00.00.0Accounts payableEV/GC (X)30.424.321.018.9Short-term debtCROCI (%)(53.3)163.821.235.1Short-term lease liabilitiesROIC (%)(48.4)142.834.545.3Other current liabilitiesROA (%)(18.6)57.014.118.0Total current liabilitiesDays inventory outst, sales----Long-term debtAsset turnover (X)4.021.514.919.2Long-term lease liabilitiesCapex/D&A (%)94.947.251.170.0Other long-term liabilitiesNet debt/equity (excl. leases) (%)(57.3)(52.2)(54.8)(59.8)Total long-term liabilitiesEBIT interest cover (X)(123.5)39.0184.920.9Total liabilitiesFCF cover of dividends (X)----Preferred shares",
      "page": 1,
      "section": null
    },
    {
      "passage_id": "6b90ecb30f181541",
      "text": "Growth & Margins (%)12/2412/25E12/26E12/27ETotal revenue growth(58.2)682.4(36.1)25.6Total liabilities & equityEBITDA growth(185.6)635.8(63.9)44.6Capital employedEBIT growth(190.5)635.8(63.9)44.6Add for unfunded pensions & GWNet inc. growth(177.2)664.9(61.8)31.8Cash Flow (Skr mn)EPS growth(177.1)665.1(61.8)31.8DPS growthNMNMNMNMNet incomeD&A addbackMinority interest addbackNet (incl./dec working capitalOther operating cash flowCash flow from operationsCapital expendituresAcquisitionsDivestituresOthersCash flow from investingRepayment of lease liabilitiesDividends paid (common & pref)Indicated in debtOther financing cash flowsCash flow from financingTotal cash flowReinvestment rate (%)",
      "page": 1,
      "section": null
    },
    {
      "passage_id": "ada55303dbab6495",
      "text": "Price PerformanceBIOAb.ST (Skr)S&P 5003507,0003006,5002506,0002005,5001505,0001004,500Oct-24Jan-25Apr-25Jul-253m6m12mAbsolute69.9%26.3%85.6%Rel. to the S&P 50055.5%16.4%60.6%",
      "page": 1,
      "section": null
    },
    {
      "passage_id": "4c1d7069d31c2051",
      "text": "Source: FactSet. Price as of 1 Sep 2025 close.",
      "page": 1,
      "section": null
    },
    {
      "passage_id": "250029831818acb8",
      "text": "Income Statement (Skr mn)12/2412/25E12/26E12/27ETotal revenue257.42,013.41,286.11,615.5Total operating expenses(175.8)(259.0)(337.8)(419.0)R&D(311.1)(424.9)(510.0)(561.0)Other operating inc./exp.)-1.1(105.0)4.14.3EBITDA(228.5)1,224.5442.4639.8Depreciation & amortisation0.00.00.00.0EBIT(228.5)1,224.5442.4639.8Net interest inc./exp.)39.05.034.9(10.9)Income/(loss) from associates----Profit/(loss) on disposals----Total other net----Pre-tax profit(189.5)1,229.5477.3628.9Provision for taxes12.5(229.4)(95.5)(125.8)Minority interest----Preferred dividends----Net inc. (pre-exceptions)(177.0)1,000.1381.8503.1Post-tax exceptions----Net inc. (post-exceptions)(177.0)1,000.1381.8503.1EPS (basic, pre-except) (Skr)(2.00)11.324.325.70EPS (basic, post-except) (Skr)(2.00)11.324.325.70Wtd avg shares out. (basic) (mn)88.388.388.388.3Tax rate (%)6.618.720.020.0Common dividends declared0.00.00.00.0DPS (Skr)----",
      "page": 1,
      "section": null
    },
    {
      "passage_id": "e372600237856560",
      "text": "12/2412/25E12/26E12/27ECash & cash equivalents512.91,000.51,260.91,677.3Accounts receivable9.527.019.723.0Inventory----Other current assets488.31,261.31,261.31,261.3Total current assets1,010.72,288.82,541.92,961.6Net PP&E96.690.682.386.4Net intangibles----Total investments0.00.00.00.0Other long-term assets4.44.74.74.7Total assets1,111.72,384.12,628.93,052.6Accounts payable51.050.851.456.3Short-term debt----Other current lease liabilities13.114.414.414.4Other current liabilities77.8365.2225.2140.2Total current liabilities175.7430.4291.0210.9Long-term debt----Long-term lease liabilities41.135.638.038.8Total long-term liabilities0.00.00.00.0Total liabilities211.6466.0329.0249.7Preferred shares----Total common equity894.91,918.12,299.92,803.0Minority interest----Capital employed1,111.72,384.12,628.93,052.6Add for unfunded pensions & GW894.91,918.12,299.92,803.0Cash Flow (Skr mn)Net income12/2412/25E12/26E12/27ED&A addback(228.5)1,224.5442.4639.8Minority interest addback----Net (incl./dec working capital(62.6)(129.8)7.91.6Other operating cash flow(44.0)102.5(200.5)(221.7)Cash flow from operations(316.3)1,223.4282.8448.7Capital expenditures(26.6)(18.8)(24.7)(33.1)Acquisitions----Divestitures----Cash flow from investing232.236.0(738.0)-Repayment of lease liabilities205.6(720.9)(24.7)(33.1)Dividends paid (common & pref)----Indicated in debt(19.7)(8.8)2.30.8Other financing cash flows25.423.00.00.0Cash flow from financing5.714.22.30.8Total cash flow(98.6)487.5260.5416.4Reinvestment rate (%)(10.5)1.49.07.4",
      "page": 1,
      "section": null
    },
    {
      "passage_id": "9f557a9caf21af3f",
      "text": "Source: Company data, Goldman Sachs Research estimates.",
      "page": 1,
      "section": null
    },
    {
      "passage_id": "f61b83ecc78944c9",
      "text": "POS for exidavnembagiven positive developments around competitor a-syn programs.",
      "page": 2,
      "section": null
    },
    {
      "passage_id": "404ec70299a68fe1",
      "text": "Key pipeline timelines were yertated and our focus remains on: 1) the progress of the BrainTransporter program BAN202, with decisions from Eisai on potential further development by the end of 2022; 2) the ongoing Phase 2 trial (EXIST) studying exidavnemba in Parkinson's disease (PD) and multiple system atrophy (MSA); 3) progress on finding a partner for exidavnemba; and 4) additional partnerships on the BrainTransporter technology.",
      "page": 2,
      "section": null
    },
    {
      "passage_id": "607678d390b04145",
      "text": "Following the earnings update, we increase our \\(12m\\) PT c.52% to SEK353 from SEK232 and remain Buy rated.",
      "page": 2,
      "section": null
    },
    {
      "passage_id": "a00bb2b2b46b6ec8",
      "text": "Exhibit 1:BlOAb BrainTransporter collaborations",
      "page": 2,
      "section": null
    },
    {
      "passage_id": "3daea45f91881c1c",
      "text": "DateCompanyTherapeutic area/IndicationAssetUpfront PaymentMilestonesRoyalties26/08/25NOVNNeurodegenerationND-BT8825$30mn$772mnMid-single digit royalties19/12/24BMYAlzheimer&#x27;s DiseaseBAN2803 /BAN1503$100mn$1250mnLow double-digit royalties20/04/24EisaiAlzheimer&#x27;s DiseaseBAN2802---",
      "page": 2,
      "section": null
    },
    {
      "passage_id": "c10dd6142102b52e",
      "text": "Source: Company data, Goldman Sachs Global Investment Research",
      "page": 2,
      "section": null
    },
    {
      "passage_id": "4ffd1d8ca6f6b3b2",
      "text": "BIOAb reported Net Revenues of SEK 392mn, \\(2\\% /3\\%\\) above GSe/Visible Alpha Consensus Data estimates of SEK 384mn/380mn, respectively. As a reminder, Leqembi sales were reported by partners BIB (covered by Salveen Richter) and Eisai (covered by Akinori Ueda) and came in at \\(\\) 160\\mathrm{mn}\\(JPY23.1bn, per Eisai), resulting in SEK 163mn in royalty revenue to BIOAb, \\(5\\% /6\\%\\) above GSe/Visible Alpha Consensus Data estimates updated after the sales release. Operating expenses came in at SEK 193mn, \\(11\\% /20\\%\\) above GSe/consensus estimates of SEK 156mn/161mn, respectively, mainly due to currency losses of SEK 32mn attributable to revenues from BMS (covered by Asad Haider). Operating profit of SEK 179mn was \\(6\\%\\) below GSe of SEK 1,144 mn and \\(12\\%\\) below consensus of SEK 1,091mn. EPS of SEK 1.09 was \\(29\\% /44\\%\\) below GSe/consensus driven by the currency loss and higher tax than anticipated.",
      "page": 2,
      "section": null
    },
    {
      "passage_id": "14289e4026aa4099",
      "text": "Exhibit 2:2025 BlOAb financials",
      "page": 2,
      "section": null
    },
    {
      "passage_id": "20bc98d56efe622e",
      "text": "SEKmn, except EPS data2Q25ReportedGSeVs GSeCompany ConsVs Company ConsRoyalties to BIOAb1631555%1536%Total revenue3923842%3803%Total OpEx19317411%16120%EBIT179190(6%)203(12%)Net profit (loss)97136(29%)--EPS - basic1.091.54(29%)1.93(44%)",
      "page": 2,
      "section": null
    },
    {
      "passage_id": "420010f8ed6bef43",
      "text": "Source: Company data, Goldman Sachs Global Investment Research, Company-compiled consensus",
      "page": 2,
      "section": null
    },
    {
      "passage_id": "9f1d50bd3f45a647",
      "text": "Management provided updated commentary on operating expenses for 2025, now anticipating an increase of \\(50\\% - 70\\%\\) vs. \\(60\\% - 80\\%\\) previously, while noting expectations for pre- tax profit to be above SEK 1bn vs. c. SEK 1bn previously. Our updated estimates are broadly in line with the mid- point of the operating expense range implied by guidance and \\(23\\%\\) above SEK 1bn on operating profit.",
      "page": 3,
      "section": null
    },
    {
      "passage_id": "2d9af1718e541f3f",
      "text": "Exhibit 3: FY25 guidance",
      "page": 3,
      "section": null
    },
    {
      "passage_id": "b0917d4ef49ef2e3",
      "text": "FY25 Soft guideMid-pointFY24AGSeGSe vs. Soft guideVA ConsVA Cons vs. Soft guideItem (SEK mn)at 1Q25at 2Q25OpexTo increase 60- 80%To increase 50- 70%734459726-1%7340%Profit before taxc. SEK1bnabove SEK1bn1,000-1901,23023%1,22222%",
      "page": 3,
      "section": null
    },
    {
      "passage_id": "8f828a615594e35b",
      "text": "Source: Company data, Goldman Sachs Global Investment Research, Visible Alpha Consensus Data",
      "page": 3,
      "section": null
    },
    {
      "passage_id": "f19d68547a0fb9ff",
      "text": "Management expects Novartis decisions on next steps in \\(\\sim 2\\) years. Management highlighted the BrainTransporter collaboration deal with Novartis for an undisclosed target in neurodegenerative diseases, noting the program is in the pre- clinical stage with development and evaluation lasting for approximately 2 years before Novartis makes a decision on next steps, which would potentially trigger milestone payments if Novartis were to decide to opt in. Additionally, BIOAb management flagged the commercial potential of the asset, pointing to a sizeable patient population expanding several indications associated with its undisclosed biological target. Recall BIOAb announced the deal on Aug 26 (see the press release here), which includes an upfront payment of \\(30mn\\) (20% of which is expected to be booked in 2025 as revenue per management on the call), with potential additional payments of up to \\(772mn\\) tiered and mid- single digit % royalties on future global product sales if the product reaches the market. Furthermore, BIOAb management underscored the deal as the third partnership for the company's BrainTransporter technology following the BMY and Eisai deals and the first with a collaboration structure where BrainTransporter is to be incorporated into the partner's molecule rather than BIOAb developing and licensing out the whole molecule. The company continues to develop multiple modalities for the technology including antibodies, enzymes, proteins, peptides, antisense molecules, and small molecules and sees potential for more partnership deals going forward with both collaboration structures under consideration.",
      "page": 3,
      "section": null
    },
    {
      "passage_id": "9f89dad1c2d969cb",
      "text": "Leqembi launch in the Nordics is expected in 2026. BIOAb management noted partner Eisai has filed for Health Technology Assessment (HTA) of Leqembi in four of the Nordic countries to initiate the pricing and reimbursement evaluation process, and despite uncertainty around timelines, BIOAb expects launch in 2026, with preparation ongoing including partnering with the PROMINENT project and REAL AD study where",
      "page": 3,
      "section": null
    },
    {
      "passage_id": "64817796db584f68",
      "text": "high interest from physicians was noted. Additionally, a Leqembi website for healthcare professionals and an annual educational event held in Stockholm were highlighted as potential drivers for drug uptake. On launches in other European countries, management noted potential infrastructure challenges similar to those in the US and a gradual roll- out given country specific reimbursement processes pointing to Austria, where the drug was launched on Aug 25, and Germany, where launch is expected on Sep 1, as being in the first batch, with potential for France and Spain to implement early access programs for Leqmebi in 4Q25.",
      "page": 4,
      "section": null
    },
    {
      "passage_id": "a090e7e81fab1659",
      "text": "Other key takeaways: 1) The company noted the collaboration program with Eisai on BAN2802 continues to progress while not commenting on timelines for potential Eisai decisions on next steps; 2) The company highlighted potential for exidavnemab in PD, MSA, and DLB (Dementia with Lewy bodies) and developments around ROG's prasinezumab in PD and Lundbeck's amlenetug in MSA as supportive for the mechanism; 3) Operating expenses for FY25 are now expected to be \\(50 - 70\\%\\) higher than 2024 levels vs. \\(60 - 80\\%\\) higher noted previously; 4) The company has options to develop rare disease programs internally driven by strong financial positions but is open to partnership; and 5) Management reiterated expectations for dividend payout to start in 2026/27 pending board approval.",
      "page": 4,
      "section": null
    },
    {
      "passage_id": "9e252651af3904d9",
      "text": "Alpha- synuclein monoclonal antibody exidavnemab is BioArctic's most advanced pipeline asset with a Phase 2 trial in Parkinson's Disease (PD) and Multiple System Atrophy (MSA) ongoing. We briefly re- cap competitor developments in the space which on balance we see as positive and thus supportive of our increased PoS for exidavnemab in PD. Notably we are monitoring Roche's prasinezumab and Lundbeck's amlenetug which like exidavnemab are also monoclonal antibodies. By reminder data from exidavnemab's Phase 2 EXIST trial in PD and MSA are expected in 1H26 into which we remain cautious even with our raised PoS.",
      "page": 4,
      "section": null
    },
    {
      "passage_id": "1ac8097d7017d8b7",
      "text": "Roche's prasinezumab in PD: In Jun 2025, Roche (covered by James Quigley) announced its decision to progress alpha- syn inhibitor prasinezumab into Phase 3 development based on results from Phase 2b PADOVA, where the drug demonstrated positive trends on delayed time to motor progression relative to placebo (the primary endpoint) with a HR of 0.84 despite failing to achieve statistical significance, whereas in a subgroup population treated with levodopa, the delay was more pronounced with a HR of 0.79 and a p- value of 0.0431 (nominal). Additionally, long- term open- label extension data showed reduced motor and functional progression in patients treated with prasinezumab relative to a real- world data arm where no prasinezumab was given.",
      "page": 4,
      "section": null
    },
    {
      "passage_id": "72ad62819be1005b",
      "text": "Lundbeck's amlenetug in MSA: In Nov 2024, Lundbeck (Coverage Suspended) announced decisions to initiate the Phase 3 MASCOT trial for alpha- syn inhibitor amlenetug in MSA based on the AMULET Phase 2 trial where the drug showed a positive trend of slowing MSA in a less impaired subgroup population despite not",
      "page": 4,
      "section": null
    },
    {
      "passage_id": "d6f9a2fd1e85f955",
      "text": "achieving statistical significance in the ITT population. The drug was subsequently granted breakthrough designation by the FDA in February 2025. We do not explicitly model MSA in our BIOAb model given the lack of supportive data but expect investors to closely monitor Lundbeck's progress as a potential proof of concept for BioArctic's exidavnemab noting the MASCOT trial has a 1H28 primary completion per clinicaltrials.gov and see the FDA breakthrough designation award as supportive of the mechanism.",
      "page": 5,
      "section": null
    },
    {
      "passage_id": "24fb72d8100d5d0e",
      "text": "Exhibit 4:BIOAb catalyst calendar",
      "page": 5,
      "section": null
    },
    {
      "passage_id": "f739126663c9d5e0",
      "text": "TimingProductEvent typeDetails2025Aug 31-25LeqembiRegulatoryPDUFA for SC maintenanceOct 21, 2025LeqembiRegulatoryEisai appeal meeting with NICE regarding UK reimbursement decisions2H25LeqembiRegulatoryFiling for SC induction2025BAN2802 (BrainTransporter)-Potential Eisai decision on further collaboration2026+1H26ExidavnemabClinicalReadout for Ph 2 EXIST in PD and MSA2Q26LeqembiRegulatoryPotential FDA decision on SC induction2027BAN2803-Potential BMY decision on further collaboration2027/2028ND-BT8825-Potential Novartis decision on further collaboration2028LeqembiClinicalReadout for Ph 3 AHEAD 3-45 in preclinical AD",
      "page": 5,
      "section": null
    },
    {
      "passage_id": "f349599c395647ab",
      "text": "Source: Company data, Goldman Sachs Global Investment Research",
      "page": 5,
      "section": null
    },
    {
      "passage_id": "60dd430a4d2c296b",
      "text": "We update our model based on 2Q25 reported financials, FX, BIOAb management comments, and developments around a- syn antibodies and roll forward our DCF by 3 months. Key changes are highlighted below:",
      "page": 5,
      "section": null
    },
    {
      "passage_id": "b2139f6d85f342a8",
      "text": "We raise our POS for exidavnemab in PD from \\(5\\%\\) to \\(15\\%\\) driven by progression of competitor programs into Phase 3 development which provides positive readacross to exidavnemab. We raise our forecasts on FY25- 26 revenue by c. \\(3\\%\\) driven by the Novartis collaboration. Our forecasts on revenue from FY28- 36 are c. \\(1 - 5\\%\\) below our prior estimates driven by FX. We lower our estimates on total operating expenses in FY25 by \\(6\\%\\) driven by updated management expectation (FY25 operating expenses now expected to be \\(50 - 70\\%\\) higher than 2024 levels vs. \\(60 - 80\\%\\) higher previously); We raise our terminal growth rate assumption from \\(0\\%\\) to \\(2\\%\\) and lower our WACC from \\(12\\%\\) to \\(10\\%\\) as we see higher long- term growth potential and lower risk for the company driven by collaboration deals announced with Novartis, BMS, and Eisai as well as further de- risking of the platform following the subcutaneous Leqembi approval.",
      "page": 5,
      "section": null
    },
    {
      "passage_id": "384d9865a53f0176",
      "text": "Our 12m price target moves c.52% higher from SEK232 to SEK353, mainly driven by changes to our WACC, terminal growth rate and upfront cash from the Novartis collaboration.",
      "page": 6,
      "section": null
    },
    {
      "passage_id": "1ee3fbf4995c3a7f",
      "text": "Exhibit 5:GSe New vs.Old",
      "page": 6,
      "section": null
    },
    {
      "passage_id": "d50609d423c1c0bb",
      "text": "SEKmn, except EPS data2025E2026E2027E2028E2029E2030E2031E2032E2033E2034E2035E2036EOLDRevenue196212541618272131003880465853265831617764216577Lecanemab royalties5199761557221829433621423947315098535855445687Lecanemab Nordic region072249102206354510628702738751Exidvanemab0005127183553628278R&amp;amp;D(490)(539)(566)(600)(630)(662)(695)(729)(766)(728)(691)(657)SG&amp;amp;A(213)(236)(250)(290)(319)(344)(361)(379)(398)(418)(439)(461)Total operating expenses(773)(771)(812)(885)(944)(1,001)(1,051)(1,103)(1,158)(1,140)(1,124)(1,111)EBIT1,1243686261,5821,8182,4653,1233,6844,0924,4274,6664,819Net Profit/Loss9182944991,2601,4541,9762,5092,9663,3023,5813,7853,919EPS10.393.335.6514.2716.4622.3728.4133.5837.3940.5542.8544.37Revenue2,0131,2861,6162,5833,0243,7664,5375,2155,7376,0916,3676,511Lecanemab royalties5189331,4932,1292,8263,4794,0744,5474,9005,1525,3325,470Lecanemab Nordic region-7214799199342493607678713726Exidvanemab----362151101154180237226R&amp;amp;D(425)(510)(561)(589)(618)(649)(682)(716)(752)(714)(678)(645)SG&amp;amp;A(196)(229)(248)(286)(315)(340)(357)(375)(394)(414)(434)(456)Total operating expenses(726)(735)(804)(871)(929)(985)(1,034)(1,086)(1,140)(1,122)(1,106)(1,094)EBIT1,2244426401,4681,7712,3843,0383,6114,0404,3834,6544,796Net Profit/Loss1,0003825031,1591,4051,8992,4272,8923,2433,5263,7533,875EPS11.324.325.7013.1315.9121.5027.4832.7536.7239.9342.4943.88Revenue3%3%(0%)(5%)(2%)(3%)(3%)(2%)(2%)(1%)(1%)(1%)Lecanemab royalties(0%)(4%)(4%)(4%)(4%)(3%)(4%)(4%)(4%)(1%)(4%)(4%)Lecanemab Nordic region(3%)(3%)(3%)(3%)(3%(3%)(3%)(3%)(3)(3%)(3%)(3%)Exidvanemab----200%198%191%191%191%191%191%-191%R&amp;amp;D(13%)(5%)(1%)(2%)(2%)(2%)(2%)(1%)(2%)(2%)(1%)(1%)SG&amp;amp;A(8%)(3%)(1%)(1%)(1%)(1%)(2%)(2%)(2%)(2%)(1%)(1%)Total operating expenses(6%)(5%)(1%)(2%)(2%)(2%)(2%)(1%)(1%)(1%)(2%)(2%)EBIT9%20%2%(7%)(3%)(3%)(3%)(2%)(1%)(1%)(0%)(0%)Net Profit/Loss9%30%1%(8%)(3%)(4%)(3%)(2%)(2%)(2%)(1%)(1%)EPS9%30%1%(8%)(3%)(4%)(3%)(2%)(2%)(2%)(1%)(1%)PTOld232New353Change52%",
      "page": 6,
      "section": null
    },
    {
      "passage_id": "7e43e1f130f141a3",
      "text": "Source:Goldman Sachs Global Investment Research",
      "page": 6,
      "section": null
    },
    {
      "passage_id": "5e8bffca067449bc",
      "text": "We are Buy rated on BioArctic, with a 12- month price target of SEK353 (from SEK232). We use a DCF methodology, and assign a WACC of \\(10\\%\\) (vs. \\(12\\%\\) previously, driven by collaboration deals) and a terminal growth rate of \\(2\\%\\) (vs. \\(0\\%\\) previously, driven by collaboration deals).",
      "page": 6,
      "section": null
    },
    {
      "passage_id": "8751aaa4cc9b8dfd",
      "text": "Key risks to our view and price target: Weak commercial performance of Leqembi; clinical trial failures for exidvanemab and additional Leqembi trials; higher- than- anticipated cash burn leading to additional financing requirement.",
      "page": 6,
      "section": null
    },
    {
      "passage_id": "566dc285fd2b7e1e",
      "text": "We, Rajan Sharma, Max Da, Ph.D. and Avantika B, hereby certify that all of the views expressed in this report accurately reflect our personal views about the subject company or companies and its or their securities. We also certify that no part of our compensation was, is or will be, directly or indirectly, related to the specific recommendations or views expressed in this report.",
      "page": 7,
      "section": null
    },
    {
      "passage_id": "f3a12276f6ea9a29",
      "text": "Unless otherwise stated, the individuals listed on the cover page of this report are analysts in Goldman Sachs' Global Investment Research division.",
      "page": 7,
      "section": null
    },
    {
      "passage_id": "00797deccff397ad",
      "text": "The Goldman Sachs Factor Profile provides investment context for a stock by comparing key attributes to the market (i.e. our universe of rated stocks) and its sector peers. The four key attributes depicted are: Growth, Financial Returns, Multiple (e.g. valuation) and Integrated (a composite of Growth, Financial Returns and Multiple). Growth, Financial Returns and Multiple are calculated by using normalized ranks for specific metrics for each stock. The normalized ranks for the metrics are then averaged and converted into percentiles for the relevant attribute. The precise calculation of each metric may vary depending on the fiscal year, industry and region, but the standard approach is as follows:",
      "page": 7,
      "section": null
    },
    {
      "passage_id": "019b8fdeca72829f",
      "text": "Growth is based on a stock's forward- looking sales growth, EBITDA growth and EPS growth (for financial stocks, only EPS and sales growth), with a higher percentile indicating a higher growth company. Financial Returns is based on a stock's forward- looking ROE, ROCE and CROCI (for financial stocks, only ROE), with a higher percentile indicating a company with higher financial returns. Multiple is based on a stock's forward- looking P/E, P/B, price/dividend (P/D), EV/EBITDA, EV/FCF and EV/Debt Adjusted Cash Flow (DACF) (for financial stocks, only P/E, P/B and P/D), with a higher percentile indicating a stock trading at a higher multiple. The Integrated percentile is calculated as the average of the Growth percentile, Financial Returns percentile and (100% - Multiple percentile).",
      "page": 7,
      "section": null
    },
    {
      "passage_id": "bc53ce16627281d3",
      "text": "Financial Returns and Multiple use the Goldman Sachs analyst forecasts at the fiscal year- end at least three quarters in the future. Growth uses inputs for the fiscal year at least seven quarters in the future compared with the year at least three quarters in the future (on a per- share basis for all metrics).",
      "page": 7,
      "section": null
    },
    {
      "passage_id": "2b04445f6b8aafb6",
      "text": "For a more detailed description of how we calculate the GS Factor Profile, please contact your GS representative.",
      "page": 7,
      "section": null
    },
    {
      "passage_id": "93d4d53adfeee211",
      "text": "Across our global coverage, we examine stocks using an M&A framework, considering both qualitative factors and quantitative factors (which may vary across sectors and regions) to incorporate the potential that certain companies could be acquired. We then assign a M&A rank as a means of scoring companies under our rated coverage from 1 to 3, with 1 representing high (30%- 50%) probability of the company becoming an acquisition target, 2 representing medium (15%- 30%) probability and 3 representing low (0%- 15%) probability. For companies ranked 1 or 2, in line with our standard departmental guidelines we incorporate an M&A component into our target price. M&A rank of 3 is considered immaterial and therefore does not factor into our price target, and may or may not be discussed in research.",
      "page": 7,
      "section": null
    },
    {
      "passage_id": "df1a680e35c0d1a7",
      "text": "Quantum is Goldman Sachs' proprietary database providing access to detailed financial statement histories, forecasts and ratios. It can be used for in- depth analysis of a single company, or to make comparisons between companies in different sectors and markets.",
      "page": 7,
      "section": null
    },
    {
      "passage_id": "5208786a5fcd49f7",
      "text": "The ratings(s) for BioArctic is/are relative to the other companies in its/their coverage universe: Argenx SE, Autolus Therapeutics, BioArctic, DBV Technologies SA, Genmab, Gubra A/S, Idorsia Pharmaceuticals, Immatics NV, Immunocore, Innate Pharma SA, Philogen S.p.A., UCB, Valneva SE, Zealand Pharma A/S",
      "page": 7,
      "section": null
    },
    {
      "passage_id": "60d22e73605fcc71",
      "text": "The following disclosures relate to relationships between The Goldman Sachs Group, Inc. (with its affiliates, \"Goldman Sachs\") and companies covered by Goldman Sachs Global Investment Research and referred to in this research.",
      "page": 7,
      "section": null
    },
    {
      "passage_id": "fb21979c337858be",
      "text": "Goldman Sachs expects to receive or intends to seek compensation for investment banking services in the next 3 months: BioArctic (Skr309.00)",
      "page": 7,
      "section": null
    },
    {
      "passage_id": "561c245d5a5a69d0",
      "text": "Goldman Sachs had an investment banking services client relationship during the past 12 months with: BioArctic (Skr309.00)",
      "page": 7,
      "section": null
    },
    {
      "passage_id": "d9284a2b091caad3",
      "text": "See company- specific regulatory disclosures above for any of the following disclosures required as to companies referred to in this report: manager or co- manager in a pending transaction; \\(1\\%\\) or other ownership; compensation for certain services; types of client relationships; managed/co- managed public offerings in prior periods; directorships; for equity securities, market making and/or specialist role. Goldman Sachs trades or may trade as a principal in debt securities (or in related derivatives) of issuers discussed in this report.",
      "page": 8,
      "section": null
    },
    {
      "passage_id": "94710c78f8ece496",
      "text": "The following are additional required disclosures: Ownership and material conflicts of interest: Goldman Sachs policy prohibits its analysts, professionals reporting to analysts and members of their households from owning securities of any company in the analyst's area of coverage. Analyst compensation: Analysts are paid in part based on the profitability of Goldman Sachs, which includes investment banking revenues. Analyst as officer or director: Goldman Sachs policy generally prohibits its analysts, persons reporting to analysts or members of their households from serving as an officer, director or advisor of any company in the analyst's area of coverage. Non- U.S. Analysts: Non- U.S. analysts may not be associated persons of Goldman Sachs & Co. LLC and therefore may not be subject to FINRA Rule 2241 or FINRA Rule 2242 restrictions on communications with subject company, public appearances and trading securities held by the analysts.",
      "page": 8,
      "section": null
    },
    {
      "passage_id": "9048b0d2654d188f",
      "text": "Distribution of ratings: See the distribution of ratings disclosure above. Price chart: See the price chart, with changes of ratings and price targets in prior periods, above, or, if electronic format or if with respect to multiple companies which are the subject of this report, on the Goldman Sachs website at https://www.gs.com/research/hedge.html.",
      "page": 8,
      "section": null
    },
    {
      "passage_id": "af5952a02c4714c1",
      "text": "The following disclosures are those required by the jurisdiction indicated, except to the extent already made above pursuant to United States laws and regulations. Australia: Goldman Sachs Australia Pty Ltd and its affiliates are not authorised deposit- taking institutions (as that term is defined in the Banking Act 1959 (Cth)) in Australia and do not provide banking services, nor carry on a banking business, in Australia. This research, and any access to it, is intended only for \"wholesale clients\" within the meaning of the Australian Corporations Act, unless otherwise agreed by Goldman Sachs. In producing research reports, members of Global Investment Research of Goldman Sachs Australia may attend site visits and other meetings hosted by the companies and other entities which are the subject of its research reports. In some instances the costs of such site visits or meetings may be met in part or in whole by the issuers concerned if Goldman Sachs Australia considers it is appropriate and reasonable in the specific circumstances relating to the site visit or meeting. To the extent that the contents of this document contains any financial product advice, it is general advice only and has been prepared by Goldman Sachs without taking into account a client's objectives, financial situation or needs. A client should, before acting on any such advice, consider the appropriateness of the advice having regard to the client's own objectives, financial situation and needs. A copy of certain Goldman Sachs Australia and New Zealand disclosure of interests and a copy of Goldman Sachs' Australian Sell- Side Research Independence Policy Statement are available at: https://www.goldmansachs.com/disclosures/australia- new- zealand/index.html. Brazil: Disclosure information in relation to CVM Resolution n. 20 is available at https://www.gs.com/worldwide/brazil/area/gr/index.html. Where applicable, the Brazil- registered analyst primarily responsible for the content of this research report, as defined in Article 20 of CVM Resolution n. 20, is the first author named at the beginning of this report, unless indicated otherwise at the end of the text. Canada: This information is being provided to you for information purposes only and is not, and under no circumstances should be construed as, an advertisement, offering or solicitation by Goldman Sachs & Co. LLC for purchasers of securities in Canada to trade in any Canadian security. Goldman Sachs & Co. LLC is not registered as a dealer in any jurisdiction in Canada under applicable Canadian securities laws and generally is not permitted to trade in Canadian securities and may be prohibited from selling certain securities and products in certain jurisdictions in Canada. If you wish to trade in any Canadian securities or other products in Canada please contact Goldman Sachs Canada Inc., an affiliate of The Goldman Sachs Group Inc., or another registered Canadian dealer. Hong Kong: Further information on the securities of covered companies referred to in this research may be obtained on request from Goldman Sachs (Asia) L.L.C. India: Further information on the subject company or companies referred to in this research may be obtained from Goldman Sachs (India) Securities Private Limited, Research Analyst - SEBI Registration Number INH000001493, 951- A, Rational House, Appasahbe Marathe Marg, Prabhadevi, Mumbai 400 025, India, Corporate Identity Number U74140MH2006FTC160634, Phone +91 22 6616 9000, Fax +91 22 6616 9001. Goldman Sachs may beneficially own 1% or more of the securities (as such term is defined in clause 2 (h) the Indian Securities Contracts (Regulation) Act, 1956) of the subject company or companies referred to in this research report. Investment in securities market are subject to market risks. Read all the related documents carefully before investing. Registration granted by SEBI and certification from NISM in no way guarantee performance of the intermediary or provide any assurance of returns to investors. Goldman Sachs (India) Securities Private Limited compliance officer and investor grievance contact details can be found at this link: https://publishing.gs.com/disclosures/hedge.html - /general/equity. Japan: See below. Korea: This research, and any access to it, is intended only for \"professional investors\" within the meaning of the Financial Services and Capital Markets Act, unless otherwise agreed by Goldman Sachs. Further information on the subject company or companies referred to in this research may be obtained from Goldman Sachs (Asia) L.L.C., Seoul Branch. New Zealand: Goldman Sachs New Zealand Limited and its affiliates are neither \"registered banks\" nor \"deposit takers\" (as defined in the Reserve Bank of New Zealand Act 1989) in New Zealand. This research, and any access to it, is intended for \"wholesale clients\" (as defined in the Financial Advisers Act 2008) unless otherwise agreed by Goldman Sachs. A copy of certain Goldman Sachs Australia and New Zealand disclosure of interests is available at:",
      "page": 8,
      "section": null
    },
    {
      "passage_id": "02464b6b7574c864",
      "text": "https://www.goldmansachs.com/disclosures/australia- new- zealand/index.html Russia: Research reports distributed in the Russian Federation are not advertising as defined in the Russian legislation, but are information and analysis not having product promotion as their main purpose and do not provide appraisal within the meaning of the Russian legislation on appraisal activity. Research reports do not constitute a personalized investment recommendation as defined in Russian laws and regulations, are not addressed to a specific client, and are prepared without analyzing the financial circumstances, investment profiles or risk profiles of clients. Goldman Sachs assumes no responsibility for any investment decisions that may be taken by a client or any other person based on this research report. Singapore: Goldman Sachs (Singapore) Pte. (Company Number: 198602165W), which is regulated by the Monetary Authority of Singapore, accepts legal responsibility for this research, and should be contacted with respect to any matters arising from, or in connection with, this research. Taiwan: This material is for reference only and must not be reprinted without permission. Investors should carefully consider their own investment risk. Investment results are the responsibility of the individual investor. United Kingdom: Persons who would be categorized as retail clients in the United Kingdom, as such term is defined in the rules of the Financial Conduct Authority, should read this research in conjunction with prior Goldman Sachs research on the covered companies referred to herein and should refer to the risk warnings that have been sent to them by Goldman Sachs International. A copy of these risks warnings, and a glossary of certain financial terms used in this report, are available from Goldman Sachs International on request.",
      "page": 9,
      "section": null
    },
    {
      "passage_id": "773559544cf98c3f",
      "text": "European Union and United Kingdom: Disclosure information in relation to Article 6 (2) of the European Commission Delegated Regulation (EU) (2016/958) supplementing Regulation (EU) No 596/2014 of the European Parliament and of the Council (including as that Delegated Regulation is implemented into United Kingdom domestic law and regulation following the United Kingdom's departure from the European Union and the European Economic Area) with regard to regulatory technical standards for the technical arrangements for objective presentation of investment recommendations or other information recommending or suggesting an investment strategy and for disclosure of particular interests or indications of conflicts of interest is available at https://www.gs.com/disclosures/europeanpolicy.html which states the European Policy for Managing Conflicts of Interest in Connection with Investment Research.",
      "page": 9,
      "section": null
    },
    {
      "passage_id": "bad137aa1e42e8fb",
      "text": "Japan: Goldman Sachs Japan Co., Ltd. is a Financial Instrument Dealer registered with the Kanto Financial Bureau under registration number Kinsho 69, and a member of Japan Securities Dealers Association, Financial Futures Association of Japan Type II Financial Instruments Firms Association, The Investment Trusts Association, Japan, and Japan Investment Advisers Association. Sales and purchase of equities are subject to commission pre- determined with clients plus consumption tax. See company- specific disclosures as to any applicable disclosures required by Japanese stock exchanges, the Japanese Securities Dealers Association or the Japanese Securities Finance Company.",
      "page": 9,
      "section": null
    },
    {
      "passage_id": "83a5b1ebf9e5705c",
      "text": "Buy (B), Neutral (N), Sell (S) Analysts recommend stocks as Buys or Sells for inclusion on various regional Investment Lists. Being assigned a Buy or Sell on an Investment List is determined by a stock's total return potential relative to its coverage universe. Any stock not assigned as a Buy or a Sell on an Investment List with an active rating (i.e., a stock that is not Rating Suspended, Not Rated, Early- Stage Biotech, Coverage Suspended or Not Covered), is deemed Neutral. Each region manages Regional Conviction Lists, which are selected from Buy rated stocks on the respective region's Investment Lists and represent investment recommendations focused on the size of the total return potential and/or the likelihood of the realization of the return across their respective areas of coverage. The addition or removal of stocks from such Conviction Lists are managed by the Investment Review Committee or other designated committee in each respective region and do not represent a change in the analysts' investment rating for such stocks.",
      "page": 9,
      "section": null
    },
    {
      "passage_id": "3f1489f5bb026b11",
      "text": "Total return potential represents the upside or downside differential between the current share price and the price target, including all paid or anticipated dividends, expected during the time horizon associated with the price target. Price targets are required for all covered stocks. The total return potential, price target and associated time horizon are stated in each report adding or reiterating an Investment List membership.",
      "page": 9,
      "section": null
    },
    {
      "passage_id": "d2fd2cf4f7721c10",
      "text": "Coverage Universe: A list of all stocks in each coverage universe is available by primary analyst, stock and coverage universe at https://www.gs.com/research/hedge.html.",
      "page": 9,
      "section": null
    },
    {
      "passage_id": "d8cb8018a2599b63",
      "text": "Not Rated (NR). The investment rating, target price and earnings estimates (where relevant) are removed pursuant to Goldman Sachs policy when Goldman Sachs is acting in an advisory capacity in a merger or in a strategic transaction involving this company, when there are legal, regulatory or policy constraints due to Goldman Sachs' involvement in a transaction, and in certain other circumstances. Early- Stage Biotech (ES). An investment rating and a target price are not assigned pursuant to Goldman Sachs policy when this company neither has a drug, treatment or medical device that has passed a Phase II clinical trial nor a license to distribute a post- Phase II drug, treatment or medical device. Rating Suspended (RS). Goldman Sachs Research has suspended the investment rating and price target for this stock, because there is not a sufficient fundamental basis for determining an investment rating or target price. The previous investment rating and target price, if any, are no longer in effect for this stock and should not be relied upon. Coverage Suspended (CS). Goldman Sachs has suspended coverage of this company. Not Covered (NC). Goldman Sachs does not cover this company.",
      "page": 9,
      "section": null
    },
    {
      "passage_id": "1a0d31455e5ce226",
      "text": "Goldman Sachs International (\"GSI\"), authorised by the Prudential Regulation Authority (\"PRA\") and regulated by the Financial Conduct Authority (\"FCA\") and the PRA, has approved this research in connection with its distribution in the United Kingdom.",
      "page": 9,
      "section": null
    },
    {
      "passage_id": "1275730d81b0b7c3",
      "text": "European Economic Area: GSI, authorised by the PRA and regulated by the FCA and the PRA, disseminates research in the following jurisdictions within the European Economic Area: the Grand Duchy of Luxembourg, Italy, the Kingdom of Belgium, the Kingdom of Denmark, the Kingdom of Norway, the Republic of Finland and the Republic of Ireland; GSI - Succursale de Paris (Paris branch) which is authorised by the French Autorite de controle prudentiel et de resolution (\"ACPR\") and regulated by the Autorite de controle prudentiel et de resolution and the Autorite des marches financiers (\"AMF\") disseminates research in France; GSI - Sucursal en Espana (Madrid branch) authorized in Spain by the Comision Nacional del Mercado de Valores disseminates research in the Kingdom of Spain; GSI - Sweden Bankfilial (Stockholm branch) is authorized by the SFSA as a \"third country branch\" in accordance with Chapter 4, Section 4 of the Swedish Securities and Market Act (Sw. lag (2007:528) om vardepappersmarknaden) disseminates research in the Kingdom of Sweden; Goldman Sachs Bank Europe SE (\"GSBE\") is a credit institution incorporated in Germany and, within the Single Supervisory Mechanism, subject to direct prudential supervision by the European Central Bank and in other respects supervised by German Federal Financial Supervisory Authority (Bundesanstalt fur Finanzdienstleistungsaufsicht, BaFin) and Deutsche Bundesbank and disseminates research",
      "page": 9,
      "section": null
    },
    {
      "passage_id": "977b269e36bb8ebd",
      "text": "in the Federal Republic of Germany and those jurisdictions within the European Economic Area where GSI is not authorised to disseminate research and additionally, GSE, Copenhagen Branch filial of GSE, Tyskland, supervised by the Danish Financial Authority disseminates research in the Kingdom of Denmark; GSE - Sucursal en Espa√±a (Madrid branch) subject to a limited extent) to local supervision by the Bank of Spain disseminates research in the Kingdom of Spain; GSE - Sucursale Italia (Milan branch) to the relevant applicable extent, subject to local supervision by the Bank of Italy (Banca d'Italia) and the Italian Companies and Exchange Commission (Commissione Nazionale per le Societa e la Borsa \"Consob\") disseminates research in Italy; GSE - Sucursale de Paris (Paris branch), supervised by the AMF and by the ACPR disseminates research in France; and GSE - Sweden Banklial (Stockholm branch), to a limited extent, subject to local supervision by the Swedish Financial Supervisory Authority (Finansinspektionen) disseminates research in the Kingdom of Sweden.",
      "page": 10,
      "section": null
    },
    {
      "passage_id": "064a7b7759748578",
      "text": "This research is for our clients only. Other than disclosures relating to Goldman Sachs, this research is based on current public information that we consider reliable, but we do not represent it as accurate or complete, and it should not be relied on as such. The information, opinions, estimates and forecasts contained herein are as of the date hereof and are subject to change without prior notification. We seek to update our research as appropriate, but various regulations may prevent us from doing so. Other than certain industry reports published on a periodic basis, the large majority of reports are published at irregular intervals as appropriate in the analyst's judgment.",
      "page": 10,
      "section": null
    },
    {
      "passage_id": "9f2e1cce4043bfed",
      "text": "Goldman Sachs conducts a global full- service, integrated investment banking, investment management, and brokerage business. We have investment banking and other business relationships with a substantial percentage of the companies covered by Global Investment Research. Goldman Sachs & Co. LLC, the United States broker dealer, is a member of SIPC (https://www.sipc.org).",
      "page": 10,
      "section": null
    },
    {
      "passage_id": "6640b932779710b5",
      "text": "Our salespeople, traders, and other professionals may provide oral or written market commentary or trading strategies to our clients and principal trading desks that reflect opinions that are contrary to the opinions expressed in this research. Our asset management area, principal trading desks and investing businesses may make investment decisions that are inconsistent with the recommendations or views expressed in this research.",
      "page": 10,
      "section": null
    },
    {
      "passage_id": "b64ea9d0867d85dc",
      "text": "The analysts named in this report may have from time to time discussed with our clients, including Goldman Sachs salespersons and traders, or may discuss in this report, trading strategies that reference catalysts or events that may have a near- term impact on the market price of the equity securities discussed in this report, which impact may be directionally counter to the analyst's published price target expectations for such stocks. Any such trading strategies are distinct from and do not affect the analyst's fundamental equity rating for such stocks, which rating reflects a stock's return potential relative to its coverage universe as described herein.",
      "page": 10,
      "section": null
    },
    {
      "passage_id": "8986170acdcec321",
      "text": "We and our affiliates, officers, directors, and employees will from time to time have long or short positions in, act as principal in, and buy or sell, the securities or derivatives, if any, referred to in this research, unless otherwise prohibited by regulation or Goldman Sachs policy.",
      "page": 10,
      "section": null
    },
    {
      "passage_id": "06fd6fb1217e5f1b",
      "text": "The views attributed to third party presenters at Goldman Sachs arranged conferences, including individuals from other parts of Goldman Sachs, do not necessarily reflect those of Global Investment Research and are not an official view of Goldman Sachs.",
      "page": 10,
      "section": null
    },
    {
      "passage_id": "134d8f858981d235",
      "text": "Any third party referenced herein, including any salespeople, traders and other professionals or members of their household, may have positions in the products mentioned that are inconsistent with the views expressed by analysts named in this report.",
      "page": 10,
      "section": null
    },
    {
      "passage_id": "67a0ed61863b298f",
      "text": "This research is not an offer to sell or the solicitation of an offer to buy any security in any jurisdiction where such an offer or solicitation would be illegal. It does not constitute a personal recommendation or take into account the particular investment objectives, financial situations, or needs of individual clients. Clients should consider whether any advice or recommendation in this research is suitable for their particular circumstances and, if appropriate, seek professional advice, including tax advice. The price and value of investments referred to in this research and the income from them may fluctuate. Past performance is not a guide to future performance, future returns are not guaranteed, and a loss of original capital may occur. Fluctuations in exchange rates could have adverse effects on the value or price of, or income derived from, certain investments.",
      "page": 10,
      "section": null
    },
    {
      "passage_id": "ac54f160788697fd",
      "text": "Certain transactions, including those involving futures, options, and other derivatives, give rise to substantial risk and are not suitable for all investors. Investors should review current options and futures disclosure documents which are available from Goldman Sachs sales representatives or at https://www.theocc.com/about/publications/character- risks.jsp and https://www.goldmansachs.com/disclosures/cftc_fcm_disclosures. Transaction costs may be significant in option strategies calling for multiple purchase and sales of options such as spreads. Supporting documentation will be supplied upon request.",
      "page": 10,
      "section": null
    },
    {
      "passage_id": "dceb7e0db8267285",
      "text": "Differing Levels of Service provided by Global Investment Research: The level and types of services provided to you by Goldman Sachs Global Investment Research may vary as compared to that provided to internal and other external clients of GS, depending on various factors including your individual preferences as to the frequency and manner of receiving communication, your risk profile and investment focus and perspective (e.g., marketwide, sector specific, long term, short term), the size and scope of your overall client relationship with GS, and legal and regulatory constraints. As an example, certain clients may request to receive notifications when research on specific securities is published, and certain clients may request that specific data underlying analysts' fundamental analysis available on our internal client websites be delivered to them electronically through data feeds or otherwise. No change to an analyst's fundamental research views (e.g., ratings, price targets, or material changes to earnings estimates for equity securities), will be communicated to any client prior to inclusion of such information in a research report broadly disseminated through electronic publication to our internal client websites or through other means, as necessary, to all clients who are entitled to receive such reports.",
      "page": 10,
      "section": null
    },
    {
      "passage_id": "b2b2b29cb6f143ea",
      "text": "All research reports are disseminated and available to all clients simultaneously through electronic publication to our internal client websites. Not all research content is redistributed to our clients or available to third- party aggregators, nor is Goldman Sachs responsible for the redistribution of our research by third party aggregators. For research, models or other data related to one or more securities, markets or asset classes (including related services) that may be available to you, please contact your GS representative or go to https://research.gs.com.",
      "page": 10,
      "section": null
    },
    {
      "passage_id": "d79d9657c0cea665",
      "text": "Disclosure information is also available at https://www.gs.com/research/hedge.html or from Research Compliance, 200 West Street, New York, NY 10282.",
      "page": 10,
      "section": null
    },
    {
      "passage_id": "be68a86ea085f5b9",
      "text": "You are permitted to store, display, analyze, modify, reformat, and print the information made available to you via this service only for your own use. You may not resell or reverse engineer this information to calculate or develop any index for disclosure and/or marketing or create any other derivative works or commercial product(s), data or offering(s) without the express written consent of Goldman Sachs. You are not permitted to publish, transmit, or otherwise reproduce this information, in whole or in part, in any format to any third party without the express written consent of Goldman Sachs. This foregoing restriction includes, without limitation, using, extracting, downloading or retrieving this information, in whole or in part, to train or finetune a machine learning or artificial intelligence system, or to provide or reproduce this information, in whole or in part, as a prompt or input to any such system.",
      "page": 10,
      "section": null
    }
  ],
  "entities": [
    {
      "entity_id": "5258d621969df642",
      "name": "AMULET Phase",
      "type": "company",
      "aliases": []
    },
    {
      "entity_id": "6afac77b7140b4ce",
      "name": "Advisers Association",
      "type": "company",
      "aliases": []
    },
    {
      "entity_id": "177bfecfcf5bcca9",
      "name": "Akinori Ueda",
      "type": "company",
      "aliases": []
    },
    {
      "entity_id": "0b7770fe3c1b61c9",
      "name": "Appasahbe Marathe",
      "type": "company",
      "aliases": []
    },
    {
      "entity_id": "628c6c952bc2160b",
      "name": "Argenx SE",
      "type": "company",
      "aliases": []
    },
    {
      "entity_id": "d960ac6d8c6330f9",
      "name": "Asad Haider",
      "type": "company",
      "aliases": []
    },
    {
      "entity_id": "6d4488d766412406",
      "name": "Australia Pty",
      "type": "company",
      "aliases": []
    },
    {
      "entity_id": "facedae141187a9f",
      "name": "Australian Corporations",
      "type": "company",
      "aliases": []
    },
    {
      "entity_id": "37943b86af92d90f",
      "name": "Australian Sell",
      "type": "company",
      "aliases": []
    },
    {
      "entity_id": "cf35663b05f7f0e1",
      "name": "Autolus Therapeutics",
      "type": "company",
      "aliases": []
    },
    {
      "entity_id": "10c4b9fb39db2245",
      "name": "Bank Europe",
      "type": "company",
      "aliases": []
    },
    {
      "entity_id": "665d58562cca56d1",
      "name": "Banking Act",
      "type": "company",
      "aliases": []
    },
    {
      "entity_id": "e0bc6c2fd37a4105",
      "name": "BlOAb BrainTransporter",
      "type": "company",
      "aliases": []
    },
    {
      "entity_id": "7cf340f0ce82f127",
      "name": "CVM Resolution",
      "type": "company",
      "aliases": []
    },
    {
      "entity_id": "13eec11f9f77d58d",
      "name": "Canada Inc",
      "type": "company",
      "aliases": []
    },
    {
      "entity_id": "98bf4640b315d632",
      "name": "Capital Markets",
      "type": "company",
      "aliases": []
    },
    {
      "entity_id": "dc62425edd02dcb2",
      "name": "Cash Flow",
      "type": "company",
      "aliases": []
    },
    {
      "entity_id": "957e6dc08022ce1d",
      "name": "Comision Nacional",
      "type": "company",
      "aliases": []
    },
    {
      "entity_id": "958d1b456afc4433",
      "name": "Commissione Nazionale",
      "type": "company",
      "aliases": []
    },
    {
      "entity_id": "5fe1df7c254a8bcd",
      "name": "Company Cons",
      "type": "company",
      "aliases": []
    }
  ],
  "data": {
    "figures": [
      {
        "type": "combo",
        "title": "Goldman Sachs rating and stock price target history",
        "page": 9,
        "axes": {
          "x": {
            "type": "category",
            "labels": [
              "A 2022",
              "S 2022",
              "O 2022",
              "N 2022",
              "D 2022",
              "J 2023",
              "F 2023",
              "M 2023",
              "A 2023",
              "M 2023",
              "J 2023",
              "J 2023",
              "A 2023",
              "S 2023",
              "O 2023",
              "N 2023",
              "D 2023",
              "J 2024",
              "F 2024",
              "M 2024",
              "A 2024",
              "M 2024",
              "J 2024",
              "J 2024",
              "A 2024",
              "S 2024",
              "O 2024",
              "N 2024",
              "D 2024",
              "J 2025",
              "F 2025",
              "M 2025",
              "A 2025",
              "M 2025",
              "J 2025"
            ]
          },
          "y": {
            "unit": "Swedish Krona",
            "range": {
              "min": 0,
              "max": 400
            }
          },
          "y2": {
            "unit": "Swedish Krona",
            "range": {
              "min": 3000,
              "max": 7000
            }
          }
        },
        "series": [
          {
            "name": "Stock Price",
            "unit": "Swedish Krona",
            "values": [
              80,
              90,
              100,
              110,
              105,
              100,
              95,
              105,
              115,
              120,
              110,
              100,
              90,
              85,
              95,
              100,
              110,
              120,
              130,
              140,
              150,
              160,
              170,
              180,
              190,
              200,
              210,
              220,
              230,
              240,
              250,
              260,
              270,
              280,
              290
            ]
          },
          {
            "name": "Index Price",
            "unit": "Swedish Krona",
            "values": [
              4500,
              4700,
              4800,
              5000,
              5200,
              5500,
              5800,
              6000,
              6200,
              6500,
              6300,
              6000,
              5800,
              5500,
              5200,
              5000,
              4800,
              4500,
              4300,
              4000,
              3800,
              3500,
              3300,
              3000,
              3200,
              3500,
              3800,
              4000,
              4200,
              4500,
              4800,
              5000,
              5200,
              5500,
              5800
            ]
          },
          {
            "name": "Rating",
            "unit": "Swedish Krona",
            "values": [
              null,
              null,
              null,
              null,
              null,
              null,
              null,
              null,
              null,
              null,
              null,
              null,
              null,
              null,
              null,
              null,
              null,
              354,
              342,
              336,
              345,
              347,
              292,
              286,
              278,
              316,
              308,
              267,
              237,
              null,
              null,
              null,
              null,
              null,
              null
            ]
          }
        ],
        "figure_id": "11ecc00e47463c6b",
        "provenance": {
          "page": 9
        }
      },
      {
        "type": "bar",
        "title": "Factor Profile",
        "page": 1,
        "axes": {
          "x": {
            "type": "value",
            "labels": [
              "Percentile",
              "20th",
              "40th",
              "60th",
              "80th",
              "100th"
            ]
          },
          "y": {
            "unit": "category",
            "range": {
              "min": null,
              "max": null
            }
          }
        },
        "series": [
          {
            "name": "BIOAb.ST relative to Europe Coverage",
            "unit": "Percentile",
            "values": [
              98,
              83,
              99,
              60
            ]
          },
          {
            "name": "BIOAb.ST relative to Europe Biotech",
            "unit": "Percentile",
            "values": [
              58,
              80,
              48,
              65
            ]
          }
        ],
        "figure_id": "b0a0472126ab555e",
        "provenance": {
          "page": 1
        }
      }
    ],
    "tables": [],
    "numerical_data": [
      {
        "num_id": "d4c985e9b313f4c8",
        "value": 0.142,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "onal step toward platform validation BIOAb.ST 12m Price Target: Skr353.00 Price: Skr309.00 Upside: 14.2% BioArctic reported 2Q25 earnings which were largely in- line with expectations given the key me",
        "provenance": {
          "page": 0
        }
      },
      {
        "num_id": "3328ea7afcf9443f",
        "value": 30.0,
        "unit": "$",
        "metric_type": "currency",
        "context": "vartis collaboration as a key positive development for BioArctic bringing meaningful upfront cash (\\$30mn) and adding to collaborations with BMS and Eisai (Exhibit 1). Whilst we await clinical data to",
        "provenance": {
          "page": 0
        }
      },
      {
        "num_id": "966556d8b7d9cbb9",
        "value": 2.9,
        "unit": "$",
        "metric_type": "currency",
        "context": "assurance on long- term revenue expectations. We also raise our Key Data Market cap: Skr27.3bn / \\$2.9bn Enterprise value: Skr26.3bn / \\$2.8bn 3m ADTV: Skr52.0mn / \\$5.4mn Sweden Europe Biotech M&A Ra",
        "provenance": {
          "page": 0
        }
      },
      {
        "num_id": "60cc1d94d94afd15",
        "value": 2.8,
        "unit": "$",
        "metric_type": "currency",
        "context": "ations. We also raise our Key Data Market cap: Skr27.3bn / \\$2.9bn Enterprise value: Skr26.3bn / \\$2.8bn 3m ADTV: Skr52.0mn / \\$5.4mn Sweden Europe Biotech M&A Rank: 3 Leases incl. in net debt & EV?: ",
        "provenance": {
          "page": 0
        }
      },
      {
        "num_id": "c1ab99ec18594b1f",
        "value": 5.4,
        "unit": "$",
        "metric_type": "currency",
        "context": "y Data Market cap: Skr27.3bn / \\$2.9bn Enterprise value: Skr26.3bn / \\$2.8bn 3m ADTV: Skr52.0mn / \\$5.4mn Sweden Europe Biotech M&A Rank: 3 Leases incl. in net debt & EV?: Yes GS Forecast <table><tr><",
        "provenance": {
          "page": 0
        }
      },
      {
        "num_id": "708095ae37c7de03",
        "value": 0.6990000000000001,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "<td></td><td></td><td>3m</td><td>6m</td><td>12m</td><td></td></tr><tr><td>Absolute</td><td></td><td>69.9%</td><td>26.3%</td><td>85.6%</td><td></td></tr><tr><td>Rel. to the S&P 500</td><td></td><td>55.",
        "provenance": {
          "page": 1
        }
      },
      {
        "num_id": "3ad5d74fd2df240c",
        "value": 0.263,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "/td><td>3m</td><td>6m</td><td>12m</td><td></td></tr><tr><td>Absolute</td><td></td><td>69.9%</td><td>26.3%</td><td>85.6%</td><td></td></tr><tr><td>Rel. to the S&P 500</td><td></td><td>55.5%</td><td>16.",
        "provenance": {
          "page": 1
        }
      },
      {
        "num_id": "3a70ed449e8eecf1",
        "value": 0.856,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "><td>6m</td><td>12m</td><td></td></tr><tr><td>Absolute</td><td></td><td>69.9%</td><td>26.3%</td><td>85.6%</td><td></td></tr><tr><td>Rel. to the S&P 500</td><td></td><td>55.5%</td><td>16.4%</td><td>60.",
        "provenance": {
          "page": 1
        }
      },
      {
        "num_id": "56273f3d0339019d",
        "value": 0.555,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "td>69.9%</td><td>26.3%</td><td>85.6%</td><td></td></tr><tr><td>Rel. to the S&P 500</td><td></td><td>55.5%</td><td>16.4%</td><td>60.6%</td><td></td></tr></table> Source: FactSet. Price as of 1 Sep 2025",
        "provenance": {
          "page": 1
        }
      },
      {
        "num_id": "95fb8185eb33b704",
        "value": 0.16399999999999998,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "td>26.3%</td><td>85.6%</td><td></td></tr><tr><td>Rel. to the S&P 500</td><td></td><td>55.5%</td><td>16.4%</td><td>60.6%</td><td></td></tr></table> Source: FactSet. Price as of 1 Sep 2025 close. <table",
        "provenance": {
          "page": 1
        }
      },
      {
        "num_id": "a2f3f64d3d558dcd",
        "value": 0.606,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "td>85.6%</td><td></td></tr><tr><td>Rel. to the S&P 500</td><td></td><td>55.5%</td><td>16.4%</td><td>60.6%</td><td></td></tr></table> Source: FactSet. Price as of 1 Sep 2025 close. <table><tr><td>Incom",
        "provenance": {
          "page": 1
        }
      },
      {
        "num_id": "20e83e0eefecaa18",
        "value": 0.52,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "ps on the BrainTransporter technology. Following the earnings update, we increase our \\(12m\\) PT c.52% to SEK353 from SEK232 and remain Buy rated. Exhibit 1:BlOAb BrainTransporter collaborations <tabl",
        "provenance": {
          "page": 2
        }
      },
      {
        "num_id": "b1257b80bff13c81",
        "value": 0.05,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "ny Cons</td><td>Vs Company Cons</td></tr><tr><td>Royalties to BIOAb</td><td>163</td><td>155</td><td>5%</td><td>153</td><td>6%</td></tr><tr><td>Total revenue</td><td>392</td><td>384</td><td>2%</td><td>",
        "provenance": {
          "page": 2
        }
      },
      {
        "num_id": "54fea47faef47fd0",
        "value": 0.06,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "any Cons</td></tr><tr><td>Royalties to BIOAb</td><td>163</td><td>155</td><td>5%</td><td>153</td><td>6%</td></tr><tr><td>Total revenue</td><td>392</td><td>384</td><td>2%</td><td>380</td><td>3%</td></tr",
        "provenance": {
          "page": 2
        }
      },
      {
        "num_id": "4326d6f7d49aec4c",
        "value": 0.02,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "55</td><td>5%</td><td>153</td><td>6%</td></tr><tr><td>Total revenue</td><td>392</td><td>384</td><td>2%</td><td>380</td><td>3%</td></tr><tr><td>Total OpEx</td><td>193</td><td>174</td><td>11%</td><td>16",
        "provenance": {
          "page": 2
        }
      },
      {
        "num_id": "dd91254bbfaa34dc",
        "value": 0.03,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "53</td><td>6%</td></tr><tr><td>Total revenue</td><td>392</td><td>384</td><td>2%</td><td>380</td><td>3%</td></tr><tr><td>Total OpEx</td><td>193</td><td>174</td><td>11%</td><td>161</td><td>20%</td></tr>",
        "provenance": {
          "page": 2
        }
      },
      {
        "num_id": "3eca768f651191bf",
        "value": 0.11,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "d>384</td><td>2%</td><td>380</td><td>3%</td></tr><tr><td>Total OpEx</td><td>193</td><td>174</td><td>11%</td><td>161</td><td>20%</td></tr><tr><td>EBIT</td><td>179</td><td>190</td><td>(6%)</td><td>203</",
        "provenance": {
          "page": 2
        }
      },
      {
        "num_id": "52620913a9b8f139",
        "value": 0.2,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": ">380</td><td>3%</td></tr><tr><td>Total OpEx</td><td>193</td><td>174</td><td>11%</td><td>161</td><td>20%</td></tr><tr><td>EBIT</td><td>179</td><td>190</td><td>(6%)</td><td>203</td><td>(12%)</td></tr><t",
        "provenance": {
          "page": 2
        }
      },
      {
        "num_id": "63ca4a76c01383ff",
        "value": 0.06,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "><td>174</td><td>11%</td><td>161</td><td>20%</td></tr><tr><td>EBIT</td><td>179</td><td>190</td><td>(6%)</td><td>203</td><td>(12%)</td></tr><tr><td>Net profit (loss)</td><td>97</td><td>136</td><td>(29%",
        "provenance": {
          "page": 2
        }
      },
      {
        "num_id": "df221a8d1459c818",
        "value": 0.12,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "<td>161</td><td>20%</td></tr><tr><td>EBIT</td><td>179</td><td>190</td><td>(6%)</td><td>203</td><td>(12%)</td></tr><tr><td>Net profit (loss)</td><td>97</td><td>136</td><td>(29%)</td><td>-</td><td>-</td",
        "provenance": {
          "page": 2
        }
      },
      {
        "num_id": "bbcba1a2ac7a89b2",
        "value": 0.29,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "d>(6%)</td><td>203</td><td>(12%)</td></tr><tr><td>Net profit (loss)</td><td>97</td><td>136</td><td>(29%)</td><td>-</td><td>-</td></tr><tr><td>EPS - basic</td><td>1.09</td><td>1.54</td><td>(29%)</td><t",
        "provenance": {
          "page": 2
        }
      },
      {
        "num_id": "e6a394b44bfa9a10",
        "value": 0.29,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "6</td><td>(29%)</td><td>-</td><td>-</td></tr><tr><td>EPS - basic</td><td>1.09</td><td>1.54</td><td>(29%)</td><td>1.93</td><td>(44%)</td></tr></table> Source: Company data, Goldman Sachs Global Investm",
        "provenance": {
          "page": 2
        }
      },
      {
        "num_id": "0f1d447fa2299a9c",
        "value": 0.44,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "td><td>-</td></tr><tr><td>EPS - basic</td><td>1.09</td><td>1.54</td><td>(29%)</td><td>1.93</td><td>(44%)</td></tr></table> Source: Company data, Goldman Sachs Global Investment Research, Company-compi",
        "provenance": {
          "page": 2
        }
      },
      {
        "num_id": "46c1a1322d0196bf",
        "value": 30.0,
        "unit": "$",
        "metric_type": "currency",
        "context": "oyalties</td></tr><tr><td>26/08/25</td><td>NOVN</td><td>Neurodegeneration</td><td>ND-BT8825</td><td>$30mn</td><td>$772mn</td><td>Mid-single digit royalties</td></tr><tr><td>19/12/24</td><td>BMY</td><t",
        "provenance": {
          "page": 2
        }
      },
      {
        "num_id": "04640b9920315a18",
        "value": 772.0,
        "unit": "$",
        "metric_type": "currency",
        "context": "/tr><tr><td>26/08/25</td><td>NOVN</td><td>Neurodegeneration</td><td>ND-BT8825</td><td>$30mn</td><td>$772mn</td><td>Mid-single digit royalties</td></tr><tr><td>19/12/24</td><td>BMY</td><td>Alzheimer&#x",
        "provenance": {
          "page": 2
        }
      },
      {
        "num_id": "794ddfe672e462c1",
        "value": 100.0,
        "unit": "$",
        "metric_type": "currency",
        "context": "</tr><tr><td>19/12/24</td><td>BMY</td><td>Alzheimer&#x27;s Disease</td><td>BAN2803 /BAN1503</td><td>$100mn</td><td>$1250mn</td><td>Low double-digit royalties</td></tr><tr><td>20/04/24</td><td>Eisai</t",
        "provenance": {
          "page": 2
        }
      },
      {
        "num_id": "a45b71ccaf97b5b0",
        "value": 1250.0,
        "unit": "$",
        "metric_type": "currency",
        "context": "/12/24</td><td>BMY</td><td>Alzheimer&#x27;s Disease</td><td>BAN2803 /BAN1503</td><td>$100mn</td><td>$1250mn</td><td>Low double-digit royalties</td></tr><tr><td>20/04/24</td><td>Eisai</td><td>Alzheimer",
        "provenance": {
          "page": 2
        }
      },
      {
        "num_id": "0d8aab7c6d95d507",
        "value": 0.8,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "<tr><td>Item (SEK mn)</td><td>at 1Q25</td><td>at 2Q25</td></tr><tr><td>Opex</td><td>To increase 60- 80%</td><td>To increase 50- 70%</td><td>734</td><td>459</td><td>726</td><td>-1%</td><td>734</td><td>",
        "provenance": {
          "page": 3
        }
      },
      {
        "num_id": "16a764e977d6ce75",
        "value": 0.7,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "d>at 1Q25</td><td>at 2Q25</td></tr><tr><td>Opex</td><td>To increase 60- 80%</td><td>To increase 50- 70%</td><td>734</td><td>459</td><td>726</td><td>-1%</td><td>734</td><td>0%</td></tr><tr><td>Profit b",
        "provenance": {
          "page": 3
        }
      },
      {
        "num_id": "378ecc356b85a826",
        "value": -0.01,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "/td><td>To increase 60- 80%</td><td>To increase 50- 70%</td><td>734</td><td>459</td><td>726</td><td>-1%</td><td>734</td><td>0%</td></tr><tr><td>Profit before tax</td><td>c. SEK1bn</td><td>above SEK1bn",
        "provenance": {
          "page": 3
        }
      },
      {
        "num_id": "5fe4a113d6280cf4",
        "value": 0.0,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "80%</td><td>To increase 50- 70%</td><td>734</td><td>459</td><td>726</td><td>-1%</td><td>734</td><td>0%</td></tr><tr><td>Profit before tax</td><td>c. SEK1bn</td><td>above SEK1bn</td><td>1,000</td><td>-",
        "provenance": {
          "page": 3
        }
      },
      {
        "num_id": "729c93a89a96fd9c",
        "value": 0.23,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "before tax</td><td>c. SEK1bn</td><td>above SEK1bn</td><td>1,000</td><td>-190</td><td>1,230</td><td>23%</td><td>1,222</td><td>22%</td></tr></table> Source: Company data, Goldman Sachs Global Investment",
        "provenance": {
          "page": 3
        }
      },
      {
        "num_id": "9cf3d6d2527130c5",
        "value": 0.22,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "1bn</td><td>above SEK1bn</td><td>1,000</td><td>-190</td><td>1,230</td><td>23%</td><td>1,222</td><td>22%</td></tr></table> Source: Company data, Goldman Sachs Global Investment Research, Visible Alpha ",
        "provenance": {
          "page": 3
        }
      },
      {
        "num_id": "e012566aa2e4f1ce",
        "value": 0.2,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "ced the deal on Aug 26 (see the press release here), which includes an upfront payment of \\(30mn\\) (20% of which is expected to be booked in 2025 as revenue per management on the call), with potential",
        "provenance": {
          "page": 3
        }
      },
      {
        "num_id": "d033c56247867f19",
        "value": 0.52,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "Our 12m price target moves c.52% higher from SEK232 to SEK353, mainly driven by changes to our WACC, terminal growth rate and upfron",
        "provenance": {
          "page": 6
        }
      },
      {
        "num_id": "13dccb29c00b9db9",
        "value": 0.03,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "><td>32.75</td><td>36.72</td><td>39.93</td><td>42.49</td><td>43.88</td></tr><tr><td>Revenue</td><td>3%</td><td>3%</td><td>(0%)</td><td>(5%)</td><td>(2%)</td><td>(3%)</td><td>(3%)</td><td>(2%)</td><td>",
        "provenance": {
          "page": 6
        }
      },
      {
        "num_id": "bb23bb9466afea8a",
        "value": 0.03,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "/td><td>36.72</td><td>39.93</td><td>42.49</td><td>43.88</td></tr><tr><td>Revenue</td><td>3%</td><td>3%</td><td>(0%)</td><td>(5%)</td><td>(2%)</td><td>(3%)</td><td>(3%)</td><td>(2%)</td><td>(2%)</td><t",
        "provenance": {
          "page": 6
        }
      },
      {
        "num_id": "55b0a71c5bdc1633",
        "value": 0.0,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "2</td><td>39.93</td><td>42.49</td><td>43.88</td></tr><tr><td>Revenue</td><td>3%</td><td>3%</td><td>(0%)</td><td>(5%)</td><td>(2%)</td><td>(3%)</td><td>(3%)</td><td>(2%)</td><td>(2%)</td><td>(1%)</td><",
        "provenance": {
          "page": 6
        }
      },
      {
        "num_id": "5bfa02a57c6b7eac",
        "value": 0.05,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "93</td><td>42.49</td><td>43.88</td></tr><tr><td>Revenue</td><td>3%</td><td>3%</td><td>(0%)</td><td>(5%)</td><td>(2%)</td><td>(3%)</td><td>(3%)</td><td>(2%)</td><td>(2%)</td><td>(1%)</td><td>(1%)</td><",
        "provenance": {
          "page": 6
        }
      },
      {
        "num_id": "f375e73d46bbcf91",
        "value": 0.02,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": ".49</td><td>43.88</td></tr><tr><td>Revenue</td><td>3%</td><td>3%</td><td>(0%)</td><td>(5%)</td><td>(2%)</td><td>(3%)</td><td>(3%)</td><td>(2%)</td><td>(2%)</td><td>(1%)</td><td>(1%)</td><td>(1%)</td><",
        "provenance": {
          "page": 6
        }
      },
      {
        "num_id": "28a8b67dcba4be31",
        "value": 0.03,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "3.88</td></tr><tr><td>Revenue</td><td>3%</td><td>3%</td><td>(0%)</td><td>(5%)</td><td>(2%)</td><td>(3%)</td><td>(3%)</td><td>(2%)</td><td>(2%)</td><td>(1%)</td><td>(1%)</td><td>(1%)</td></tr><tr><td>L",
        "provenance": {
          "page": 6
        }
      },
      {
        "num_id": "167ee53688e0870b",
        "value": 0.03,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "><tr><td>Revenue</td><td>3%</td><td>3%</td><td>(0%)</td><td>(5%)</td><td>(2%)</td><td>(3%)</td><td>(3%)</td><td>(2%)</td><td>(2%)</td><td>(1%)</td><td>(1%)</td><td>(1%)</td></tr><tr><td>Lecanemab roya",
        "provenance": {
          "page": 6
        }
      },
      {
        "num_id": "ffd175cc2355c59c",
        "value": 0.02,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "nue</td><td>3%</td><td>3%</td><td>(0%)</td><td>(5%)</td><td>(2%)</td><td>(3%)</td><td>(3%)</td><td>(2%)</td><td>(2%)</td><td>(1%)</td><td>(1%)</td><td>(1%)</td></tr><tr><td>Lecanemab royalties</td><td",
        "provenance": {
          "page": 6
        }
      },
      {
        "num_id": "af32cbfb32c5406f",
        "value": 0.02,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "%</td><td>3%</td><td>(0%)</td><td>(5%)</td><td>(2%)</td><td>(3%)</td><td>(3%)</td><td>(2%)</td><td>(2%)</td><td>(1%)</td><td>(1%)</td><td>(1%)</td></tr><tr><td>Lecanemab royalties</td><td>(0%)</td><td",
        "provenance": {
          "page": 6
        }
      },
      {
        "num_id": "19e81832a54b0bf6",
        "value": 0.01,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "/td><td>(0%)</td><td>(5%)</td><td>(2%)</td><td>(3%)</td><td>(3%)</td><td>(2%)</td><td>(2%)</td><td>(1%)</td><td>(1%)</td><td>(1%)</td></tr><tr><td>Lecanemab royalties</td><td>(0%)</td><td>(4%)</td><td",
        "provenance": {
          "page": 6
        }
      },
      {
        "num_id": "744c9298368a7432",
        "value": 0.01,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "/td><td>(5%)</td><td>(2%)</td><td>(3%)</td><td>(3%)</td><td>(2%)</td><td>(2%)</td><td>(1%)</td><td>(1%)</td><td>(1%)</td></tr><tr><td>Lecanemab royalties</td><td>(0%)</td><td>(4%)</td><td>(4%)</td><td",
        "provenance": {
          "page": 6
        }
      },
      {
        "num_id": "77d9fef9cb6d9b5a",
        "value": 0.01,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "/td><td>(2%)</td><td>(3%)</td><td>(3%)</td><td>(2%)</td><td>(2%)</td><td>(1%)</td><td>(1%)</td><td>(1%)</td></tr><tr><td>Lecanemab royalties</td><td>(0%)</td><td>(4%)</td><td>(4%)</td><td>(4%)</td><td",
        "provenance": {
          "page": 6
        }
      },
      {
        "num_id": "fe2d557d44532b6c",
        "value": 0.0,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": ")</td><td>(2%)</td><td>(1%)</td><td>(1%)</td><td>(1%)</td></tr><tr><td>Lecanemab royalties</td><td>(0%)</td><td>(4%)</td><td>(4%)</td><td>(4%)</td><td>(4%)</td><td>(3%)</td><td>(4%)</td><td>(4%)</td><",
        "provenance": {
          "page": 6
        }
      },
      {
        "num_id": "1c2b5fd518d30b5b",
        "value": 0.04,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": ")</td><td>(1%)</td><td>(1%)</td><td>(1%)</td></tr><tr><td>Lecanemab royalties</td><td>(0%)</td><td>(4%)</td><td>(4%)</td><td>(4%)</td><td>(4%)</td><td>(3%)</td><td>(4%)</td><td>(4%)</td><td>(4%)</td><",
        "provenance": {
          "page": 6
        }
      },
      {
        "num_id": "1c2b5fd518d30b5b",
        "value": 0.04,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": ")</td><td>(1%)</td><td>(1%)</td></tr><tr><td>Lecanemab royalties</td><td>(0%)</td><td>(4%)</td><td>(4%)</td><td>(4%)</td><td>(4%)</td><td>(3%)</td><td>(4%)</td><td>(4%)</td><td>(4%)</td><td>(1%)</td><",
        "provenance": {
          "page": 6
        }
      },
      {
        "num_id": "6c6213399b89b1d7",
        "value": 0.04,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": ")</td><td>(1%)</td></tr><tr><td>Lecanemab royalties</td><td>(0%)</td><td>(4%)</td><td>(4%)</td><td>(4%)</td><td>(4%)</td><td>(3%)</td><td>(4%)</td><td>(4%)</td><td>(4%)</td><td>(1%)</td><td>(4%)</td><",
        "provenance": {
          "page": 6
        }
      },
      {
        "num_id": "46010be40295101e",
        "value": 0.04,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": ")</td></tr><tr><td>Lecanemab royalties</td><td>(0%)</td><td>(4%)</td><td>(4%)</td><td>(4%)</td><td>(4%)</td><td>(3%)</td><td>(4%)</td><td>(4%)</td><td>(4%)</td><td>(1%)</td><td>(4%)</td><td>(4%)</td><",
        "provenance": {
          "page": 6
        }
      },
      {
        "num_id": "f64426f62ac2a350",
        "value": 0.03,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "r><td>Lecanemab royalties</td><td>(0%)</td><td>(4%)</td><td>(4%)</td><td>(4%)</td><td>(4%)</td><td>(3%)</td><td>(4%)</td><td>(4%)</td><td>(4%)</td><td>(1%)</td><td>(4%)</td><td>(4%)</td></tr><tr><td>L",
        "provenance": {
          "page": 6
        }
      },
      {
        "num_id": "6b6231911142ff72",
        "value": 0.04,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "ab royalties</td><td>(0%)</td><td>(4%)</td><td>(4%)</td><td>(4%)</td><td>(4%)</td><td>(3%)</td><td>(4%)</td><td>(4%)</td><td>(4%)</td><td>(1%)</td><td>(4%)</td><td>(4%)</td></tr><tr><td>Lecanemab Nord",
        "provenance": {
          "page": 6
        }
      },
      {
        "num_id": "668d85ff9a817533",
        "value": 0.04,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "/td><td>(0%)</td><td>(4%)</td><td>(4%)</td><td>(4%)</td><td>(4%)</td><td>(3%)</td><td>(4%)</td><td>(4%)</td><td>(4%)</td><td>(1%)</td><td>(4%)</td><td>(4%)</td></tr><tr><td>Lecanemab Nordic region</td",
        "provenance": {
          "page": 6
        }
      },
      {
        "num_id": "0bf871e6420affd7",
        "value": 0.04,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "/td><td>(4%)</td><td>(4%)</td><td>(4%)</td><td>(4%)</td><td>(3%)</td><td>(4%)</td><td>(4%)</td><td>(4%)</td><td>(1%)</td><td>(4%)</td><td>(4%)</td></tr><tr><td>Lecanemab Nordic region</td><td>(3%)</td",
        "provenance": {
          "page": 6
        }
      },
      {
        "num_id": "22ef55a0be947da9",
        "value": 0.01,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "/td><td>(4%)</td><td>(4%)</td><td>(4%)</td><td>(3%)</td><td>(4%)</td><td>(4%)</td><td>(4%)</td><td>(1%)</td><td>(4%)</td><td>(4%)</td></tr><tr><td>Lecanemab Nordic region</td><td>(3%)</td><td>(3%)</td",
        "provenance": {
          "page": 6
        }
      },
      {
        "num_id": "0bf871e6420affd7",
        "value": 0.04,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "/td><td>(4%)</td><td>(4%)</td><td>(3%)</td><td>(4%)</td><td>(4%)</td><td>(4%)</td><td>(1%)</td><td>(4%)</td><td>(4%)</td></tr><tr><td>Lecanemab Nordic region</td><td>(3%)</td><td>(3%)</td><td>(3%)</td",
        "provenance": {
          "page": 6
        }
      },
      {
        "num_id": "cdc864deea7c6a7b",
        "value": 0.04,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "/td><td>(4%)</td><td>(3%)</td><td>(4%)</td><td>(4%)</td><td>(4%)</td><td>(1%)</td><td>(4%)</td><td>(4%)</td></tr><tr><td>Lecanemab Nordic region</td><td>(3%)</td><td>(3%)</td><td>(3%)</td><td>(3%)</td",
        "provenance": {
          "page": 6
        }
      },
      {
        "num_id": "44041fc1967a74f7",
        "value": 0.03,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "d><td>(4%)</td><td>(1%)</td><td>(4%)</td><td>(4%)</td></tr><tr><td>Lecanemab Nordic region</td><td>(3%)</td><td>(3%)</td><td>(3%)</td><td>(3%)</td><td>(3%</td><td>(3%)</td><td>(3%)</td><td>(3%)</td><t",
        "provenance": {
          "page": 6
        }
      },
      {
        "num_id": "6d8a240b5a7c930d",
        "value": 0.03,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "d><td>(1%)</td><td>(4%)</td><td>(4%)</td></tr><tr><td>Lecanemab Nordic region</td><td>(3%)</td><td>(3%)</td><td>(3%)</td><td>(3%)</td><td>(3%</td><td>(3%)</td><td>(3%)</td><td>(3%)</td><td>(3)</td><td",
        "provenance": {
          "page": 6
        }
      },
      {
        "num_id": "d01f9aa41bad22e4",
        "value": 0.03,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "d><td>(4%)</td><td>(4%)</td></tr><tr><td>Lecanemab Nordic region</td><td>(3%)</td><td>(3%)</td><td>(3%)</td><td>(3%)</td><td>(3%</td><td>(3%)</td><td>(3%)</td><td>(3%)</td><td>(3)</td><td>(3%)</td><td",
        "provenance": {
          "page": 6
        }
      },
      {
        "num_id": "d1c5cc5c0b519257",
        "value": 0.03,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "d><td>(4%)</td></tr><tr><td>Lecanemab Nordic region</td><td>(3%)</td><td>(3%)</td><td>(3%)</td><td>(3%)</td><td>(3%</td><td>(3%)</td><td>(3%)</td><td>(3%)</td><td>(3)</td><td>(3%)</td><td>(3%)</td><td",
        "provenance": {
          "page": 6
        }
      },
      {
        "num_id": "97ed3f6479d96cb9",
        "value": 0.03,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "d></tr><tr><td>Lecanemab Nordic region</td><td>(3%)</td><td>(3%)</td><td>(3%)</td><td>(3%)</td><td>(3%</td><td>(3%)</td><td>(3%)</td><td>(3%)</td><td>(3)</td><td>(3%)</td><td>(3%)</td><td>(3%)</td></t",
        "provenance": {
          "page": 6
        }
      },
      {
        "num_id": "d1bbeefc20c12d92",
        "value": 0.03,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "td>Lecanemab Nordic region</td><td>(3%)</td><td>(3%)</td><td>(3%)</td><td>(3%)</td><td>(3%</td><td>(3%)</td><td>(3%)</td><td>(3%)</td><td>(3)</td><td>(3%)</td><td>(3%)</td><td>(3%)</td></tr><tr><td>Ex",
        "provenance": {
          "page": 6
        }
      },
      {
        "num_id": "a0798917f7c9713d",
        "value": 0.03,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "Nordic region</td><td>(3%)</td><td>(3%)</td><td>(3%)</td><td>(3%)</td><td>(3%</td><td>(3%)</td><td>(3%)</td><td>(3%)</td><td>(3)</td><td>(3%)</td><td>(3%)</td><td>(3%)</td></tr><tr><td>Exidvanemab</td",
        "provenance": {
          "page": 6
        }
      },
      {
        "num_id": "f6f2318dd743ebdb",
        "value": 0.03,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "</td><td>(3%)</td><td>(3%)</td><td>(3%)</td><td>(3%)</td><td>(3%</td><td>(3%)</td><td>(3%)</td><td>(3%)</td><td>(3)</td><td>(3%)</td><td>(3%)</td><td>(3%)</td></tr><tr><td>Exidvanemab</td><td>-</td><t",
        "provenance": {
          "page": 6
        }
      },
      {
        "num_id": "c1db9350969557e7",
        "value": 0.03,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": ")</td><td>(3%)</td><td>(3%)</td><td>(3%</td><td>(3%)</td><td>(3%)</td><td>(3%)</td><td>(3)</td><td>(3%)</td><td>(3%)</td><td>(3%)</td></tr><tr><td>Exidvanemab</td><td>-</td><td>-</td><td>-</td><td>-</",
        "provenance": {
          "page": 6
        }
      },
      {
        "num_id": "c5f326c39c20efb8",
        "value": 0.03,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": ")</td><td>(3%)</td><td>(3%</td><td>(3%)</td><td>(3%)</td><td>(3%)</td><td>(3)</td><td>(3%)</td><td>(3%)</td><td>(3%)</td></tr><tr><td>Exidvanemab</td><td>-</td><td>-</td><td>-</td><td>-</td><td>200%</",
        "provenance": {
          "page": 6
        }
      },
      {
        "num_id": "864a6e508cf1c1c0",
        "value": 0.03,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": ")</td><td>(3%</td><td>(3%)</td><td>(3%)</td><td>(3%)</td><td>(3)</td><td>(3%)</td><td>(3%)</td><td>(3%)</td></tr><tr><td>Exidvanemab</td><td>-</td><td>-</td><td>-</td><td>-</td><td>200%</td><td>198%</",
        "provenance": {
          "page": 6
        }
      },
      {
        "num_id": "3554e5c5c86df827",
        "value": 2.0,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "><td>(3%)</td><td>(3%)</td></tr><tr><td>Exidvanemab</td><td>-</td><td>-</td><td>-</td><td>-</td><td>200%</td><td>198%</td><td>191%</td><td>191%</td><td>191%</td><td>191%</td><td>191%</td><td>-</td><td",
        "provenance": {
          "page": 6
        }
      },
      {
        "num_id": "d099ce5d2d11a77d",
        "value": 1.98,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "><td>(3%)</td></tr><tr><td>Exidvanemab</td><td>-</td><td>-</td><td>-</td><td>-</td><td>200%</td><td>198%</td><td>191%</td><td>191%</td><td>191%</td><td>191%</td><td>191%</td><td>-</td><td>191%</td></t",
        "provenance": {
          "page": 6
        }
      },
      {
        "num_id": "673f66068d1317a4",
        "value": 1.91,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "></tr><tr><td>Exidvanemab</td><td>-</td><td>-</td><td>-</td><td>-</td><td>200%</td><td>198%</td><td>191%</td><td>191%</td><td>191%</td><td>191%</td><td>191%</td><td>-</td><td>191%</td></tr><tr><td row",
        "provenance": {
          "page": 6
        }
      },
      {
        "num_id": "b0c1694f9088b893",
        "value": 1.91,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": ">Exidvanemab</td><td>-</td><td>-</td><td>-</td><td>-</td><td>200%</td><td>198%</td><td>191%</td><td>191%</td><td>191%</td><td>191%</td><td>191%</td><td>-</td><td>191%</td></tr><tr><td rowspan=\"6\"></td",
        "provenance": {
          "page": 6
        }
      },
      {
        "num_id": "16874d26090a497e",
        "value": 1.91,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "/td><td>-</td><td>-</td><td>-</td><td>-</td><td>200%</td><td>198%</td><td>191%</td><td>191%</td><td>191%</td><td>191%</td><td>191%</td><td>-</td><td>191%</td></tr><tr><td rowspan=\"6\"></td><td>R&amp;am",
        "provenance": {
          "page": 6
        }
      },
      {
        "num_id": "cd192561af73ec9d",
        "value": 1.91,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "><td>-</td><td>-</td><td>-</td><td>200%</td><td>198%</td><td>191%</td><td>191%</td><td>191%</td><td>191%</td><td>191%</td><td>-</td><td>191%</td></tr><tr><td rowspan=\"6\"></td><td>R&amp;amp;D</td><td>(",
        "provenance": {
          "page": 6
        }
      },
      {
        "num_id": "b255fef19c5a4620",
        "value": 1.91,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "d>-</td><td>-</td><td>200%</td><td>198%</td><td>191%</td><td>191%</td><td>191%</td><td>191%</td><td>191%</td><td>-</td><td>191%</td></tr><tr><td rowspan=\"6\"></td><td>R&amp;amp;D</td><td>(13%)</td><td>",
        "provenance": {
          "page": 6
        }
      },
      {
        "num_id": "e6e6aac6b212d674",
        "value": 1.91,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "00%</td><td>198%</td><td>191%</td><td>191%</td><td>191%</td><td>191%</td><td>191%</td><td>-</td><td>191%</td></tr><tr><td rowspan=\"6\"></td><td>R&amp;amp;D</td><td>(13%)</td><td>(5%)</td><td>(1%)</td><",
        "provenance": {
          "page": 6
        }
      },
      {
        "num_id": "a1e532d3e81f64a9",
        "value": 0.13,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "191%</td><td>191%</td><td>-</td><td>191%</td></tr><tr><td rowspan=\"6\"></td><td>R&amp;amp;D</td><td>(13%)</td><td>(5%)</td><td>(1%)</td><td>(2%)</td><td>(2%)</td><td>(2%)</td><td>(2%)</td><td>(1%)</td>",
        "provenance": {
          "page": 6
        }
      },
      {
        "num_id": "0d8f58a5236c80a3",
        "value": 0.05,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "91%</td><td>-</td><td>191%</td></tr><tr><td rowspan=\"6\"></td><td>R&amp;amp;D</td><td>(13%)</td><td>(5%)</td><td>(1%)</td><td>(2%)</td><td>(2%)</td><td>(2%)</td><td>(2%)</td><td>(1%)</td><td>(2%)</td><",
        "provenance": {
          "page": 6
        }
      },
      {
        "num_id": "bdff4cca26054896",
        "value": 0.01,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "</td><td>191%</td></tr><tr><td rowspan=\"6\"></td><td>R&amp;amp;D</td><td>(13%)</td><td>(5%)</td><td>(1%)</td><td>(2%)</td><td>(2%)</td><td>(2%)</td><td>(2%)</td><td>(1%)</td><td>(2%)</td><td>(2%)</td><",
        "provenance": {
          "page": 6
        }
      },
      {
        "num_id": "e77fc80a716cf29c",
        "value": 0.02,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "</td></tr><tr><td rowspan=\"6\"></td><td>R&amp;amp;D</td><td>(13%)</td><td>(5%)</td><td>(1%)</td><td>(2%)</td><td>(2%)</td><td>(2%)</td><td>(2%)</td><td>(1%)</td><td>(2%)</td><td>(2%)</td><td>(1%)</td><",
        "provenance": {
          "page": 6
        }
      },
      {
        "num_id": "29dbd3fa90eb8d72",
        "value": 0.02,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "><td rowspan=\"6\"></td><td>R&amp;amp;D</td><td>(13%)</td><td>(5%)</td><td>(1%)</td><td>(2%)</td><td>(2%)</td><td>(2%)</td><td>(2%)</td><td>(1%)</td><td>(2%)</td><td>(2%)</td><td>(1%)</td><td>(1%)</td><",
        "provenance": {
          "page": 6
        }
      },
      {
        "num_id": "dcb8cdc7ab9b5178",
        "value": 0.02,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "\"6\"></td><td>R&amp;amp;D</td><td>(13%)</td><td>(5%)</td><td>(1%)</td><td>(2%)</td><td>(2%)</td><td>(2%)</td><td>(2%)</td><td>(1%)</td><td>(2%)</td><td>(2%)</td><td>(1%)</td><td>(1%)</td></tr><tr><td>S",
        "provenance": {
          "page": 6
        }
      },
      {
        "num_id": "ba35576de5dce8a7",
        "value": 1.0,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "percentile is calculated as the average of the Growth percentile, Financial Returns percentile and (100% - Multiple percentile). Financial Returns and Multiple use the Goldman Sachs analyst forecasts ",
        "provenance": {
          "page": 7
        }
      },
      {
        "num_id": "34154709a1fd3af3",
        "value": 0.3,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "ank as a means of scoring companies under our rated coverage from 1 to 3, with 1 representing high (30%- 50%) probability of the company becoming an acquisition target, 2 representing medium (15%- 30%",
        "provenance": {
          "page": 7
        }
      },
      {
        "num_id": "f534185f980b27af",
        "value": 0.5,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "s a means of scoring companies under our rated coverage from 1 to 3, with 1 representing high (30%- 50%) probability of the company becoming an acquisition target, 2 representing medium (15%- 30%) pro",
        "provenance": {
          "page": 7
        }
      },
      {
        "num_id": "018fcb6cffcc2c5b",
        "value": 0.15,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "g high (30%- 50%) probability of the company becoming an acquisition target, 2 representing medium (15%- 30%) probability and 3 representing low (0%- 15%) probability. For companies ranked 1 or 2, in ",
        "provenance": {
          "page": 7
        }
      },
      {
        "num_id": "e9fe225386054630",
        "value": 0.3,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "h (30%- 50%) probability of the company becoming an acquisition target, 2 representing medium (15%- 30%) probability and 3 representing low (0%- 15%) probability. For companies ranked 1 or 2, in line ",
        "provenance": {
          "page": 7
        }
      },
      {
        "num_id": "662a784b5be7fc38",
        "value": 0.0,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "ecoming an acquisition target, 2 representing medium (15%- 30%) probability and 3 representing low (0%- 15%) probability. For companies ranked 1 or 2, in line with our standard departmental guidelines",
        "provenance": {
          "page": 7
        }
      },
      {
        "num_id": "1f8cb357e831f4c8",
        "value": 0.15,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "ing an acquisition target, 2 representing medium (15%- 30%) probability and 3 representing low (0%- 15%) probability. For companies ranked 1 or 2, in line with our standard departmental guidelines we ",
        "provenance": {
          "page": 7
        }
      },
      {
        "num_id": "5df385da567a9636",
        "value": 0.01,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "40MH2006FTC160634, Phone +91 22 6616 9000, Fax +91 22 6616 9001. Goldman Sachs may beneficially own 1% or more of the securities (as such term is defined in clause 2 (h) the Indian Securities Contract",
        "provenance": {
          "page": 8
        }
      }
    ],
    "claims": [],
    "relations": [],
    "extraction_summary": {
      "figures_count": 2,
      "tables_count": 0,
      "numerical_data_count": 92,
      "passages_count": 87,
      "entities_count": 20
    }
  }
}